About Us

Persistent Efforts for Pharmaceutical Development

time:11/28/2014 page views: resource:BioBAY
Pharmaceutical development is a long and arduous process, and the persistent efforts of predecessors have provided us with much valuable experience. Currently the new drug development has become a heated area in China attracting widespread attention. The clinical research is a critical step in pharmaceutical research and development, with obvious importance. How to design the clinical research protocol, whether it meets the test requirements, whether it keeps pace with the international healthcare market, and how the clinical investigation institute and the regulatory body can accelerate the new drug filing process have always been the topics considered by drug research and development companies.
On the evening of November 26, Dr. JP Armand, chairman of French Anti-Cancer Federation, invited by Adagene and Suzhou Industrial Park Pharmaceutical Association (SIPPA), shall share his experience in clinical research at BioBAY, lighting up a lamp on the road of clinical research for companies.
Time: Wednesday, November 26, 2014
Venue: West Section, BioCAFÉ, 1/F, North Block, Building A1, BioBAY
      17: 30-18: 30 Buffer dinner 
      18: 30-20: 00 Salon

Anyone interested in the meeting may contact Ms. Zhang Xin (, 0512-6295666-6018) of BioBAY Industrial Service.

Dr. JP Armand focuses on research of the new mechanisms of cancer formation and early medications, and has been engaged in clinical drugs for decades. He founded the first Category 1 new anti-cancer drug clinical research center in Europe in 1985, and served as the medical director of European Society for Medical Oncology (ESMO), member of Clinical Research Committee of National Institute of Oncology, and chairman of ESMO Nomination Committee, and now he is a senior advisor of Gustave Roussy Cancer Hospital (Paris). He authored over 300 peer-reviewed medical papers, and acted as the member of the editorial board of Annals of Oncology, the European Journal of Cancer, etc. He received "Annual Oncologist" of ESMO in 2008, "Award for Targeted Anti-cancer Therapy" in 2013, and "British Award for Lung Cancer Research" in 2014.